Fortress Biotech - FBIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 544.40%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$0.93
▲ +0.04 (4.49%)

This chart shows the closing price for FBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fortress Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FBIO

Analyst Price Target is $6.00
▲ +544.40% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Fortress Biotech in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 544.40% upside from the last price of $0.93.

This chart shows the closing price for FBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Fortress Biotech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2022LADENBURG THALM/SH SHInitiated CoverageBuy$6.00Low
7/14/2022B. RileyLower TargetBuy$8.00 ➝ $6.00Low
5/13/2022Cantor FitzgeraldReiterated RatingBuy$6.00High
3/29/2022Roth CapitalReiterated RatingBuyHigh
12/7/2021UBS GroupReiterated RatingPositive$20.00High
11/17/2021B. RileyReiterated RatingBuyLow
10/8/2021HC WainwrightReiterated RatingBuy$10.00Low
9/29/2021B. RileyReiterated RatingBuy$8.00High
6/17/2021B. RileyLower TargetAccumulate ➝ Buy$9.00 ➝ $8.00Medium
4/20/2021Roth CapitalBoost TargetBuy$4.50 ➝ $5.00Medium
4/5/2021B. RileyReiterated RatingBuy$8.00 ➝ $9.00High
4/1/2021Cantor FitzgeraldReiterated RatingOverweightN/A
2/26/2021HC WainwrightReiterated RatingBuy$10.00Low
2/17/2021Dawson JamesBoost TargetBuy$16.00 ➝ $21.00Low
12/17/2020B. RileyReiterated RatingBuyHigh
10/13/2020Roth CapitalLower TargetBuy$5.00 ➝ $4.75High
10/12/2020HC WainwrightLower TargetBuy$11.00 ➝ $10.00High
10/2/2020BenchmarkInitiated CoverageBuy$9.00 ➝ $9.00Medium
8/21/2020B. RileyBoost Target$6.00 ➝ $8.00Low
8/12/2020B. RileyReiterated RatingBuy$6.00Medium
5/18/2020B. RileyReiterated RatingBuy$6.00Low
5/8/2020HC WainwrightReiterated RatingBuy$11.00High
3/17/2020Cantor FitzgeraldReiterated RatingOverweightHigh
3/13/2020B. RileyLower TargetBuy$9.00 ➝ $6.00Low
2/12/2020Cantor FitzgeraldInitiated CoverageOverweight$6.00High
12/18/2019B. RileyInitiated CoverageBuy$9.00High
8/26/2019Dawson JamesInitiated CoverageBuy$19.00High
7/1/2019Roth CapitalInitiated CoverageBuy$4.00Low
5/13/2019HC WainwrightReiterated RatingBuy$11.00High
2/20/2019HC WainwrightReiterated RatingBuy$11.00Medium
2/14/2019HC WainwrightSet TargetBuy$11.00High
8/10/2018HC WainwrightSet TargetBuy$11.00N/A
5/21/2018JMP SecuritiesSet TargetBuy$11.00High
5/21/2018HC WainwrightSet TargetBuy$11.00High
5/11/2018HC WainwrightSet TargetBuy$11.00High
3/27/2018HC WainwrightSet TargetBuy$11.00Low
3/16/2018HC WainwrightReiterated RatingBuy$11.00Low
2/28/2018B. RileyInitiated CoverageBuy ➝ Buy$10.00High
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/2/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/1/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/30/2022
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2023

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Fortress Biotech logo
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Read More

Today's Range

Now: $0.93
Low: $0.87
High: $0.98

50 Day Range

MA: $0.73
Low: $0.48
High: $1.10

52 Week Range

Now: $0.93
Low: $0.48
High: $2.16

Volume

450,272 shs

Average Volume

720,980 shs

Market Capitalization

$100.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Fortress Biotech?

The following Wall Street sell-side analysts have issued research reports on Fortress Biotech in the last twelve months: B. Riley, Cantor Fitzgerald, LADENBURG THALM/SH SH, Roth Capital, StockNews.com, and TheStreet.
View the latest analyst ratings for FBIO.

What is the current price target for Fortress Biotech?

3 Wall Street analysts have set twelve-month price targets for Fortress Biotech in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 544.4%. LADENBURG THALM/SH SH has the highest price target set, predicting FBIO will reach $6.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $6.00 for Fortress Biotech in the next year.
View the latest price targets for FBIO.

What is the current consensus analyst rating for Fortress Biotech?

Fortress Biotech currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FBIO will outperform the market and that investors should add to their positions of Fortress Biotech.
View the latest ratings for FBIO.

What other companies compete with Fortress Biotech?

How do I contact Fortress Biotech's investor relations team?

Fortress Biotech's physical mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company's listed phone number is (781) 652-4500 and its investor relations email address is [email protected] The official website for Fortress Biotech is www.fortressbiotech.com. Learn More about contacing Fortress Biotech investor relations.